SkinBioTherapeutics PLC SkinBiotix® generates positive data in human study (5477G)
November 07 2018 - 2:00AM
UK Regulatory
TIDMSBTX
RNS Number : 5477G
SkinBioTherapeutics PLC
07 November 2018
SkinBioTherapeutics plc
SkinBiotix(R) technology generates positive data in first two
elements of its human study
Manchester, UK - 7 November 2018 - SkinBioTherapeutics plc (AIM:
SBTX, the "Company"), a life science company focused on skin
health, announces positive data from the first two elements of its
human study which focus on skin irritancy and moisturisation
potential.
As previously announced on 19 September 2018, the third, main
element of the human study will commence later this month
(November). This will comprise 120 volunteers with self-assessed
'dry skin', and is designed to analyse the longer term
moisturisation effects and impact on skin barrier function of the
SkinBiotix(R) technology in more depth.
The elements of the study that were carried out during September
and October 2018 were as follows:
Skin Irritation Study
24-72 hours test - involved applying a cream containing
SkinBiotix(R) to 30 healthy subjects in a series of five doses of
increasing concentration. The area of skin treated was then covered
to drive absorption of the cream into the skin. At 24, 48 and 72
hours following application, subjects were assessed for any signs
of irritation. There were no instances of irritation in any of the
subjects - even at 20X the standard use dose of SkinBiotix(R).
Repetitive, longer term test - involved repeated application of
the cream at five doses to the skin of 31 healthy subjects. The
product was in contact with the skin for 12 days, using an
exaggerated exposure method to provide a more rigorous test of skin
tolerance. The volunteers were regularly monitored for signs of
irritation for up to 15 days following the initial application.
While one volunteer experienced irritation in response to the cream
(which occasionally happens in tests using prolonged exposure under
exaggerated test conditions), no irritation was observed in the
remaining 30 volunteers, even at concentrations of SkinBiotix(R)
well above that of therapeutic use (up to 20X the standard
dose).
Moisturisation Potential Study
The moisturisation effect of the SkinBiotix(R) technology was
tested in a 12 hour study - an industry standard test - using 21
healthy subjects. In this study, the cream containing SkinBiotix(R)
was applied to an area of skin and the moisture content of the skin
was measured for up to 12 hours. The moisturising effect of the
cream without the technology was also measured as a control for
comparison. As in-house laboratory tests have indicated that
SkinBiotix(R) requires at least 24 hours to produce its effects, no
difference was anticipated when compared against the control.
The cream containing SkinBiotix(R) provided good moisturisation
which was generally higher than that provided by the control cream
but the difference was not significant.
No irritation was observed in this study in any volunteer.
Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:
"Demonstrating that SkinBiotix(R) is a safe technology is a
major milestone for the Company and, as with many cosmetics, allows
for commercialisation of a product. The irritation study results
validate the safety element of our technology and provide further
reasons for potential partners to speak to us.
"We have always stated that we are a science-led company,
therefore the larger moisturisation clinical trial that is due to
commence later this month will be of key importance to us. We
expect this data will demonstrate the longer term effects of our
technology (>24 hours) and the results will play a key part in
the talks with commercial partners."
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
- Ends -
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468
Dr. Cath O'Neill, CEO 2760
Doug Quinn, CFO
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Tony Rawlinson / Sandy Jamieson / Richard
Nash
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3621
Ben Turner / James Pope 4120
Northland Capital Partners (Joint Broker)
Dugald Carlean Tel: +44 (0) 20 3861
6625
Instinctif Partners (Media Relations) Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Deborah Bell 2020
SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEAXFKEDPPFFF
(END) Dow Jones Newswires
November 07, 2018 02:00 ET (07:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024